INT122985

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 2004
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 4
Total Number 7
Disease Relevance 4.58
Pain Relevance 0.27

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (CLU) endoplasmic reticulum (CLU) lipid metabolic process (CLU)
cytoplasm (CLU) cytosol (CLU) extracellular space (CLU)
CLU (Homo sapiens)
Pain Link Frequency Relevance Heat
local anesthetic 3 97.40 Very High Very High Very High
Inflammation 3 26.52 Quite Low
Analgesic 7 25.48 Quite Low
Pain 32 5.00 Very Low Very Low Very Low
antagonist 24 5.00 Very Low Very Low Very Low
positron emission tomography 20 5.00 Very Low Very Low Very Low
palliative 8 5.00 Very Low Very Low Very Low
cva 8 5.00 Very Low Very Low Very Low
cytokine 4 5.00 Very Low Very Low Very Low
peripheral neuropathy 4 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Prostate Cancer 444 100.00 Very High Very High Very High
Disorder Of Lipid Metabolism 13 100.00 Very High Very High Very High
Recurrence 8 100.00 Very High Very High Very High
Apoptosis 40 98.44 Very High Very High Very High
Thrombocytopenia 8 88.68 High High
Mucositis 4 87.80 High High
Fatigue 16 87.36 High High
Immunotherapy Of Cancer 4 36.76 Quite Low
Death 27 35.72 Quite Low
Fever 8 10.96 Low Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In addition, ropivacaine downregulated the expression of clusterin/ apoliporotein J, a protein with anti-apoptotic properties, in a dose-dependent manner, which well correlated with the induction of apoptosis of HaCaT cells.
Negative_regulation (downregulated) of Gene_expression (expression) of clusterin associated with apoptosis
1) Confidence 0.57 Published 2004 Journal Cell Res. Section Abstract Doc Link 15538973 Disease Relevance 0.67 Pain Relevance 0.07
Ectopic expression of clusterin/apolipoprotein J or Bcl-2 decreases the sensitivity of HaCaT cells to toxic effects of ropivacaine.
Negative_regulation (decreases) of Gene_expression (expression) of clusterin associated with disorder of lipid metabolism
2) Confidence 0.41 Published 2004 Journal Cell Res. Section Title Doc Link 15538973 Disease Relevance 0.61 Pain Relevance 0.10
Ectopic expression of clusterin/apolipoprotein J or Bcl-2 decreases the sensitivity of HaCaT cells to toxic effects of ropivacaine.
Negative_regulation (decreases) of Gene_expression (expression) of apolipoprotein J associated with disorder of lipid metabolism
3) Confidence 0.41 Published 2004 Journal Cell Res. Section Title Doc Link 15538973 Disease Relevance 0.61 Pain Relevance 0.10
Several studies have demonstrated clusterin overexpression in prostate cancer especially after hormone therapy.13,39 Clustein expression has also reported to be a possible predictor for biochemical recurrence following prostatectomy.14 An antisense oligonucleotide directed against clusterin (custirsen, OGX-011) has been developed, and successful downregulation of clusterin expression was shown in primary prostate cancers in a phase I study.40
Negative_regulation (downregulation) of Gene_expression (expression) of clusterin associated with prostate cancer and recurrence
4) Confidence 0.28 Published 2010 Journal OncoTargets and therapy Section Body Doc Link PMC2895780 Disease Relevance 0.65 Pain Relevance 0
Several studies have demonstrated clusterin overexpression in prostate cancer especially after hormone therapy.13,39 Clustein expression has also reported to be a possible predictor for biochemical recurrence following prostatectomy.14 An antisense oligonucleotide directed against clusterin (custirsen, OGX-011) has been developed, and successful downregulation of clusterin expression was shown in primary prostate cancers in a phase I study.40
Negative_regulation (following) of Gene_expression (overexpression) of clusterin associated with prostate cancer and recurrence
5) Confidence 0.20 Published 2010 Journal OncoTargets and therapy Section Body Doc Link PMC2895780 Disease Relevance 0.69 Pain Relevance 0
Several studies have demonstrated clusterin overexpression in prostate cancer especially after hormone therapy.13,39 Clustein expression has also reported to be a possible predictor for biochemical recurrence following prostatectomy.14 An antisense oligonucleotide directed against clusterin (custirsen, OGX-011) has been developed, and successful downregulation of clusterin expression was shown in primary prostate cancers in a phase I study.40
Negative_regulation (following) of Gene_expression (expression) of clusterin associated with prostate cancer and recurrence
6) Confidence 0.20 Published 2010 Journal OncoTargets and therapy Section Body Doc Link PMC2895780 Disease Relevance 0.68 Pain Relevance 0
Several studies have demonstrated clusterin overexpression in prostate cancer especially after hormone therapy.13,39 Clustein expression has also reported to be a possible predictor for biochemical recurrence following prostatectomy.14 An antisense oligonucleotide directed against clusterin (custirsen, OGX-011) has been developed, and successful downregulation of clusterin expression was shown in primary prostate cancers in a phase I study.40
Negative_regulation (demonstrated) of Gene_expression (overexpression) of clusterin associated with prostate cancer and recurrence
7) Confidence 0.20 Published 2010 Journal OncoTargets and therapy Section Body Doc Link PMC2895780 Disease Relevance 0.67 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox